Key points
- An industry analysis of 4,414 Phase 1 transitions from 2011 to 2020 found that 52.0% of programs advanced to Phase 2.
- By disease area, Phase 1 success ranged from 40.9% (urology) to 71.6% (ophthalmology).
- A different method, applied to registry-based data from 2000 to 2015, estimated a higher Phase 1 success rate of 66.4%.
- Phase 1 mainly tests safety and dosing, so passing it shows a drug can be given at a tolerable dose, not that it works.
- Reported Phase 1 success rates may be inflated because some companies never publicly disclose early failures.
Phase 1 is the first time a drug candidate is given to people. Its purpose is to find out whether the drug can be given safely, and at what dose. Most estimates put the Phase 1 success rate somewhere between half and two-thirds, making it one of the easier steps in drug development.
The headline number
The largest recent industry analysis, published in 2021 by the Biotechnology Innovation Organization (BIO), Informa Pharma Intelligence, and QLS Advisors, tracked 4,414 Phase 1 transitions between 2011 and 2020. It found that 52.0% of programs advanced to Phase 2.
That is far higher than the Phase 2 success rate in the same analysis (28.9%), but it still means nearly half of drugs that reach human testing stop before their effectiveness is ever properly tested.
How Phase 1 success varies by disease area
| Disease area | Phase 1 → Phase 2 | Transitions counted |
|---|---|---|
| Ophthalmology | 71.6% | 88 |
| Hematology | 69.6% | 92 |
| Metabolic | 61.8% | 136 |
| Infectious disease | 57.8% | 403 |
| Autoimmune | 55.2% | 413 |
| All indications | 52.0% | 4,414 |
| Cardiovascular | 50.0% | 214 |
| Oncology | 48.8% | 1,628 |
| Neurology | 47.7% | 516 |
| Endocrine | 43.3% | 319 |
| Urology | 40.9% | 22 |
Source: BIO, Informa Pharma Intelligence, QLS Advisors (2021), selected disease areas. Areas with few transitions, such as urology, have less reliable estimates.
Oncology is worth noting. Cancer drugs are often too toxic to test in healthy volunteers, so their Phase 1 trials usually enroll patients. Those trials can include early signs of effect, which makes them a different kind of test from a typical healthy-volunteer study.
Why different studies give different numbers
Other analyses report different Phase 1 rates, sometimes considerably higher:
| Study | Data period | Phase 1 success rate |
|---|---|---|
| BIO, Informa, QLS (2021) | 2011–2020 | 52.0% |
| Hay et al., Nature Biotechnology (2014) | 2003–2011 | 64.5% |
| Wong, Siah, and Lo, Biostatistics (2019) | 2000–2015 | 66.4% |
These differences come mainly from method, not from drugs getting better or worse:
- What counts as a program. Some studies count each drug–indication pair separately. Others count a drug once.
- How outcomes are inferred. A program that goes quiet without an announcement may be counted as a failure, excluded, or inferred to have stopped after a period of inactivity.
- Which data source is used. Industry databases built from company disclosures and studies built from trial registries capture different sets of programs.
How these choices are made is explained in How Are Drug Approval Probabilities Calculated?
Why the real rate may be lower than reported
The BIO report itself cautions that Phase 1 success rates "may benefit from delayed reporting or omission bias." A large company running dozens of early programs may not consider a single Phase 1 failure important enough to announce. When failures go unreported, the drugs that are visible look more successful than the full population really is.
What passing Phase 1 does and does not mean
Passing Phase 1 means:
- the drug was tolerable at one or more doses,
- researchers have a picture of how the body absorbs and clears it, and
- the sponsor chose to keep investing.
It does not mean the drug works. Most Phase 1 trials are not designed to measure effectiveness, and many enroll healthy volunteers who do not have the disease. The real test of efficacy comes in Phase 2, where the largest share of drugs fail. See What Percentage of Phase 2 Drugs Get Approved?
Reading a Phase 1 announcement
When a company reports positive Phase 1 results, the useful questions are:
- Was it in healthy volunteers or patients? Signs of effect in patients carry more information.
- Was the maximum tolerated dose reached? If side effects appeared at low doses, there may be little room to increase the dose for effect.
- What were the side effects? Some early safety signals predict trouble in larger trials.
- Is there evidence the drug engages its target? Biomarker data showing the drug hits its intended target makes the later efficacy test more meaningful.
Sources
- Biotechnology Innovation Organization, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report
- Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–286.Peer-reviewed
- Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nature Biotechnology. 2014;32:40–51.Peer-reviewed
- U.S. Food and Drug Administration. Step 3: Clinical Research.Regulator
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.